Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Basun

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Alzheimer'S Research & Therapy|July 18, 2014
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's diseaseLars Lannfelt, Christer Möller, Hans Basun, et al.
Neuro-Degenerative Diseases|August 16, 2006
Clinical and molecular aspects of frontotemporal dementiaSusanne Froelich-Fabre, Lena Skoglund, Jovanka Ostojic, et al.
Journal of Alzheimer'S Disease : JAD|July 13, 2012
Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trialsBob Olsson, Clas Malmeström, Hans Basun, et al.
Journal of Alzheimer'S Disease : JAD|June 23, 2009
Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based studyJohan Sundelöf, Lena Kilander, Johanna Helmersson, et al.
Journal of Alzheimer'S Disease : JAD|September 1, 2012
Longitudinal stability evaluation of biomarkers and their correlation in cerebrospinal fluid and plasma from patients with Alzheimer's diseaseKina Höglund, Anna Bogstedt, Susanne Fabre, et al.
Journal of Alzheimer'S Disease : JAD|June 23, 2009
Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer's disease and dementia: a prospective population-based studyJohan Sundelöf, Lena Kilander, Johanna Helmersson, et al.
Molecular and Cellular Neurosciences|June 6, 2021
Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's diseaseMalin Johannesson, Charlotte Sahlin, Linda Söderberg, et al.
Brain Pathology (Zurich, Switzerland)|May 31, 2017
Rapid amyloid-β oligomer and protofibril accumulation in traumatic brain injurySami Abu Hamdeh, Erik Rollman Waara, Christer Möller, et al.
Journal of Alzheimer'S Disease : JAD|April 9, 2013
Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD studyGerd Faxén-Irving, Yvonne Freund-Levi, Maria Eriksdotter-Jönhagen, et al.
Neurogenetics|October 16, 2008
Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutationLena Skoglund, RoseMarie Brundin, Tommie Olofsson, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Alzheimer'S Research & Therapy|July 18, 2014
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's diseaseLars Lannfelt, Christer Möller, Hans Basun, et al.
Neuro-Degenerative Diseases|August 16, 2006
Clinical and molecular aspects of frontotemporal dementiaSusanne Froelich-Fabre, Lena Skoglund, Jovanka Ostojic, et al.
Journal of Alzheimer'S Disease : JAD|July 13, 2012
Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trialsBob Olsson, Clas Malmeström, Hans Basun, et al.
Journal of Alzheimer'S Disease : JAD|June 23, 2009
Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based studyJohan Sundelöf, Lena Kilander, Johanna Helmersson, et al.
Journal of Alzheimer'S Disease : JAD|September 1, 2012
Longitudinal stability evaluation of biomarkers and their correlation in cerebrospinal fluid and plasma from patients with Alzheimer's diseaseKina Höglund, Anna Bogstedt, Susanne Fabre, et al.
Journal of Alzheimer'S Disease : JAD|June 23, 2009
Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer's disease and dementia: a prospective population-based studyJohan Sundelöf, Lena Kilander, Johanna Helmersson, et al.
Molecular and Cellular Neurosciences|June 6, 2021
Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's diseaseMalin Johannesson, Charlotte Sahlin, Linda Söderberg, et al.
Brain Pathology (Zurich, Switzerland)|May 31, 2017
Rapid amyloid-β oligomer and protofibril accumulation in traumatic brain injurySami Abu Hamdeh, Erik Rollman Waara, Christer Möller, et al.
Journal of Alzheimer'S Disease : JAD|April 9, 2013
Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD studyGerd Faxén-Irving, Yvonne Freund-Levi, Maria Eriksdotter-Jönhagen, et al.
Neurogenetics|October 16, 2008
Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutationLena Skoglund, RoseMarie Brundin, Tommie Olofsson, et al.
Pageof 6